P M Wilkinson

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. pmc Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
    P M Wilkinson
    Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 94:947-54. 2006
  2. ncbi request reprint Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center
    R E Board
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
    Int J Gynecol Cancer 16:18-24. 2006
  3. ncbi request reprint ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease
    J A Radford
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    J Clin Oncol 20:2988-94. 2002
  4. pmc SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer
    A R Clamp
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK
    Br J Cancer 94:55-61. 2006
  5. pmc Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 91:639-43. 2004
  6. pmc Carcinosarcoma of the ovary
    M A Harris
    Department of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Br J Cancer 88:654-7. 2003

Detail Information

Publications6

  1. pmc Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
    P M Wilkinson
    Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 94:947-54. 2006
    ..These findings support use of epoetin alfa to increase Hb levels, reduce transfusion use, and improve QOL in anaemic ovarian cancer patients receiving platinum chemotherapy...
  2. ncbi request reprint Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center
    R E Board
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
    Int J Gynecol Cancer 16:18-24. 2006
    ..Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required...
  3. ncbi request reprint ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease
    J A Radford
    Department of Medical Oncology, Christie Hospital, Manchester, UK
    J Clin Oncol 20:2988-94. 2002
    ....
  4. pmc SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer
    A R Clamp
    Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK
    Br J Cancer 94:55-61. 2006
    ..Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted...
  5. pmc Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 91:639-43. 2004
    ..HER-2-positive breast cancer may have a predilection for the brain, or trastuzumab therapy may change the disease pattern by prolonging survival. New strategies to address this problem require investigation in this group of patients...
  6. pmc Carcinosarcoma of the ovary
    M A Harris
    Department of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Br J Cancer 88:654-7. 2003
    ..6 months. Currently, seven patients are still alive although one has cancer. The overall censored median survival was 8.7 months after a median follow-up of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively...